Wang Xiaoyi resigned as chief executive officer and chief research officer of BrainAurora Medical Technology (HKG:6681), effective June 19, a Friday filing to the Hong Kong bourse said.
Wang cited deteriorating health due to depression linked to the company's listing process as the reason for his departure, according to the filing.
Cai Longjun, currently chief technology officer and chief operating officer, has been appointed to act as CEO and CRO with immediate effect.
He will also assume legal and managerial responsibilities across BrainAurora's subsidiaries previously held by Wang.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.